Clinilabs

Clinilabs is the only global, full-service contract research organization (CRO) focused exclusively on central nervous system (CNS) drug development. With deep expertise in CNS, we are committed to the development of medicines that treat a range of psychiatric, neurological, and substance use disorders, as well as rare and ultra-rare CNS diseases. Clinilabs partners with pharmaceutical and biotechnology companies to deliver a complete, first-in-human to Phase 3 spectrum of high-quality, timely, and cost-effective clinical drug development services, with the shared goal of speeding new CNS medicines to market. We are process-driven yet structured to be nimble, providing personalized service that meets the needs of customers and projects of all sizes. Clinilabs has conducted more than 750 CNS clinical trials since 2000 and has played a pivotal role in approving 22 new therapies across 13 CNS indications to help transform patients’ lives worldwide. Clinilabs provides first-in-human through end of phase 3 services, with a global core laboratory. It is an alternative to large CROs providing a full spectrum of offerings to meet the needs of our customers world wide. Since 2000, Clinilabs has completed more than 675 clinical trials, and has worked for 15 of the top 20 pharma companies in the world, to contribute to 19 successful new drug applications (NDAs).